Organovo Holdings, Inc. (ONVO)

NASDAQ: ONVO · IEX Real-Time Price · USD
1.70
+0.06 (3.66%)
At close: Dec 9, 2022 4:00 PM
1.65
-0.05 (-2.94%)
After-hours: Dec 9, 2022 4:07 PM EST
3.66%
Market Cap 14.29M
Revenue (ttm) 1.58M
Net Income (ttm) -11.95M
Shares Out 8.71M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,819
Open 1.67
Previous Close 1.64
Day's Range 1.65 - 1.71
52-Week Range 1.45 - 4.67
Beta 1.02
Analysts Sell
Price Target n/a
Earnings Date Nov 14, 2022

About ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug com... [Read more]

Industry Biotechnology
Founded 2007
Employees 20
Stock Exchange NASDAQ
Ticker Symbol ONVO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using nov...

3 weeks ago - GlobeNewsWire

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key as...

3 months ago - GlobeNewsWire

Organovo Announces Postponement of Annual Meeting of Stockholders

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key as...

3 months ago - GlobeNewsWire

Organovo Achieves 3D Tissue Model for Crohn's Disease

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel techno...

6 months ago - GlobeNewsWire

Why Organovo Holdings, Inc. Stock Soared 49.7% This Week

The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.

9 months ago - The Motley Fool

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO...

9 months ago - GlobeNewsWire

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organ...

9 months ago - GlobeNewsWire

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo”), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one new ...

9 months ago - GlobeNewsWire

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting t...

9 months ago - GlobeNewsWire

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on how i...

10 months ago - GlobeNewsWire

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in Delawa...

10 months ago - GlobeNewsWire

Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of...

1 year ago - GlobeNewsWire

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

SOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company's annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. wa...

1 year ago - GlobeNewsWire

Catherine Wood's ARK Investment Slashes Organovo Holding

Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuti...

Other symbols: SYRS
1 year ago - GuruFocus

Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONF...

SOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences C...

1 year ago - GlobeNewsWire

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requiremen...

2 years ago - GlobeNewsWire

Organovo Announces One-for-Twenty Reverse Stock Split

SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation ...

2 years ago - GlobeNewsWire

Will Organovo Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Organovo.

3 years ago - Zacks Investment Research

What Bargain Hunting ? Tap 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E for outsized gains.

Other symbols: AVGRCYBRQLYS
3 years ago - Zacks Investment Research

Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 years ago - Zacks Investment Research

Organovo Acknowledges Receipt of Proposal

Reiterates Commitment to Strategic Review Process Reiterates Commitment to Strategic Review Process

3 years ago - GlobeNewsWire

Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates

Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

3 years ago - Zacks Investment Research

Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 years ago - Zacks Investment Research

Options Traders Expect Huge Moves in Organovo (ONVO) Stock

Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.

3 years ago - Zacks Investment Research